Clinical Trial

Monotherapy of an NMDA Enhancer for Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-08; most recent amendment 2026-03-21.
Trial Details
NCT Number NCT04745143
Lead Sponsor China Medical University Hospital
Collaborators: National Health Research Institutes, Taiwan
Conditions Schizophrenia
Enrollment 80 participants
Start Date 2018-01-01
Primary Completion 2027-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-24